First treatment approved for the management of MCD in Europe

Oprettet 04/06/2014 – 15:59

Janssen-Cilag announced today that the European Commission has approved the use of SYLVANT® for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are HIV negative and HHV-8 negative. SYLVANT® is the firts medicine to recieve regolatory approval in the EU for the treatment of MCD patients.

Skriv et svar

Din e-mailadresse vil ikke blive publiceret. Krævede felter er markeret med *